#
Lyumjev Kwikpen Intravenous, Subcutaneous
  • Drugs A to Z
  • Lyumjev Kwikpen

Lyumjev Kwikpen

Generic name:insulin lispro-aabc (intravenous route, subcutaneous route) [ IN-su-lin-LIS-pro-- aabc, ree-KOM-bi-nant ]
Drug class:Insulin

Medically reviewed by Drugs.com. Last updated on Feb 2, 2022.

Commonly used brand name(s)

In the U.S.

  • Lyumjev Kwikpen

Available Dosage Forms:

  • Solution

Therapeutic Class: Antidiabetic

Pharmacologic Class: Insulin Lispro, Recombinant

Uses for Lyumjev Kwikpen

Insulin lispro-aabc, recombinant injection is a fast-acting insulin. Insulin is used by people with diabetes to help keep blood sugar levels under control. When you have diabetes mellitus, your body cannot make enough or does not use insulin properly. So, you must take additional insulin to regulate your blood sugar and keep your body healthy. This is very important as too much sugar in your blood can be harmful to your health.

Insulin lispro-aabc starts to work faster than some other types of insulin, and its effects do not last as long. It should act more like the insulin your body would normally produce. Because the effects of insulin lispro are short-acting, your doctor may also prescribe a longer-acting insulin for you to use.

This medicine is available only with your doctor's prescription.

Before using Lyumjev Kwikpen

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies have not been performed on the relationship of age to the effects of insulin lispro-aabc injection in the pediatric population. Safety and efficacy have ...